Non-Small Cell Lung Cancer
An Open-Label, Randomized, Phase 3 Trial of Nivolumab versus Investigator’s Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
For additional information please contact Nurdan Ilgaz, Clinical Research Coordinator, at 859-260-6406. .
Small Cell Lung Cancer
Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects with Previously Untreated Extensive Stage Small-cell Lung Cancer.
For additional information please contact Heather Tudor, Clinical Research Coordinator, at 859-260-3196.